Psychosocial growth failure: a positive response to growth hormone and placebo.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

Seven children were diagnosed as having an emotional cause for growth failure.

Pretreatment growth hormone secretion profiles during sleep were analysed using PULSAR.

Who Took Part

The age groups tagged for this paper are young children and children, both men and women.

How the Study Was Run

The researchers set it up as a double-blind, placebo-controlled and crossover study.

Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Age Determination by Skeleton, Body Height, Child Development Disorders, Pervasive, Diet Surveys, Growth Disorders and Growth Hormone.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1992 (Acta paediatrica (Oslo, Norway : 1992)), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.